Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-PTX3 radioiodine-labeled probe
- Development stage
- Preclinical
- Lead developer
- Xijing Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
The anti-PTX3 radioiodine-labeled probe is a radiolabeled molecular imaging agent developed by researchers at Xijing Hospital (Fourth Military Medical University) for the detection and evaluation of cardiovascular diseases, specifically myocardial ischemia-reperfusion injury and fibrotic remodeling. The probe consists of prescreened anti-pentraxin 3 (PTX3) monoclonal antibodies or small-molecule peptides derived from antibody-binding domains, radiolabeled with iodine-124 (124I) or iodine-131 (131I). PTX3 is an inflammatory and cardiovascular biomarker that is highly and differentially expressed in injured cardiac tissue. By targeting PTX3, this probe allows for non-invasive nuclear imaging to localize and quantify myocardial injury, showing potential for integrated early screening, staged evaluation, and targeted therapy.
- Other names
- 124I-anti-PTX3131I-anti PTX3131I-anti-PTX3radioiodine-labeled anti-PTX3 probe
02
Targets
PTX3 (Pentraxin-related protein PTX3)
Beyond the preview
Go deeper on anti-PTX3 radioiodine-labeled probe.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-PTX3 radioiodine-labeled probe.